Clinical Trial Detail

NCT ID NCT03785873
Title Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Michigan Cancer Center
Indications

biliary tract cancer

Therapies

Fluorouracil + Irinotecan + Leucovorin + Nivolumab

Age Groups: adult senior

No variant requirements are available.